Literature DB >> 26700537

Small Molecule Modulators of Pre-mRNA Splicing in Cancer Therapy.

Maayan Salton1, Tom Misteli2.   

Abstract

Pre-mRNA splicing is a fundamental process in mammalian gene expression and alternative RNA splicing plays a considerable role in generating protein diversity. RNA splicing events are also key to the pathology of numerous diseases, particularly cancers. Some tumors are molecularly addicted to specific RNA splicing isoforms making interference with pre-mRNA processing a viable therapeutic strategy. Several RNA splicing modulators have recently been characterized, some showing promise in preclinical studies. While the targets of most splicing modulators are constitutive RNA processing components, possibly leading to undesirable side effects, selectivity for individual splicing events has been observed. Given the high prevalence of splicing defects in cancer, small molecule modulators of RNA processing represent a potentially promising novel therapeutic strategy in cancer treatment. Here, we review their reported effects, mechanisms, and limitations. Published by Elsevier Ltd.

Entities:  

Keywords:  cancer therapy; splicing modulators

Mesh:

Substances:

Year:  2015        PMID: 26700537      PMCID: PMC4707101          DOI: 10.1016/j.molmed.2015.11.005

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  87 in total

1.  Stalling of spliceosome assembly at distinct stages by small-molecule inhibitors of protein acetylation and deacetylation.

Authors:  Andreas N Kuhn; Maria A van Santen; Andreas Schwienhorst; Henning Urlaub; Reinhard Lührmann
Journal:  RNA       Date:  2008-11-24       Impact factor: 4.942

2.  The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region.

Authors:  Eric G Folco; Kaitlyn E Coil; Robin Reed
Journal:  Genes Dev       Date:  2011-03-01       Impact factor: 11.361

3.  Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A.

Authors:  Anna Corrionero; Belén Miñana; Juan Valcárcel
Journal:  Genes Dev       Date:  2011-03-01       Impact factor: 11.361

4.  Total synthesis of 6-deoxypladienolide D and Assessment of Splicing Inhibitory Activity in a Mutant SF3B1 cancer cell line.

Authors:  Kenzo Arai; Silvia Buonamici; Betty Chan; Laura Corson; Atsushi Endo; Baudouin Gerard; Ming-Hong Hao; Craig Karr; Kazunobu Kira; Linda Lee; Xiang Liu; Jason T Lowe; Tuoping Luo; Lisa A Marcaurelle; Yoshiharu Mizui; Marta Nevalainen; Morgan Welzel O'Shea; Eun Sun Park; Samantha A Perino; Sudeep Prajapati; Mingde Shan; Peter G Smith; Parcharee Tivitmahaisoon; John Yuan Wang; Markus Warmuth; Kuo-Ming Wu; Lihua Yu; Huiming Zhang; Guo-Zhu Zheng; Gregg F Keaney
Journal:  Org Lett       Date:  2014-10-26       Impact factor: 6.005

5.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.

Authors:  L H Boise; M González-García; C E Postema; L Ding; T Lindsten; L A Turka; X Mao; G Nuñez; C B Thompson
Journal:  Cell       Date:  1993-08-27       Impact factor: 41.582

6.  Bromodomain 4 activation predicts breast cancer survival.

Authors:  Nigel P S Crawford; Jude Alsarraj; Luanne Lukes; Renard C Walker; Jennifer S Officewala; Howard H Yang; Maxwell P Lee; Keiko Ozato; Kent W Hunter
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-21       Impact factor: 11.205

Review 7.  The spliceosome as a target of novel antitumour drugs.

Authors:  Sophie Bonnal; Luisa Vigevani; Juan Valcárcel
Journal:  Nat Rev Drug Discov       Date:  2012-11       Impact factor: 84.694

8.  Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. III. In vitro and in vivo antitumor activities.

Authors:  Yoshiharu Mizui; Takashi Sakai; Masao Iwata; Toshimitsu Uenaka; Kiyoshi Okamoto; Hajime Shimizu; Takao Yamori; Kentaro Yoshimatsu; Makoto Asada
Journal:  J Antibiot (Tokyo)       Date:  2004-03       Impact factor: 2.649

9.  Splicing factor SF3b as a target of the antitumor natural product pladienolide.

Authors:  Yoshihiko Kotake; Koji Sagane; Takashi Owa; Yuko Mimori-Kiyosue; Hajime Shimizu; Mai Uesugi; Yasushi Ishihama; Masao Iwata; Yoshiharu Mizui
Journal:  Nat Chem Biol       Date:  2007-07-22       Impact factor: 15.040

Review 10.  CD44 Acts as a Signaling Platform Controlling Tumor Progression and Metastasis.

Authors:  Véronique Orian-Rousseau
Journal:  Front Immunol       Date:  2015-04-08       Impact factor: 7.561

View more
  59 in total

1.  UXT-AS1-induced alternative splicing of UXT is associated with tumor progression in colorectal cancer.

Authors:  Jun Yin; Wei Luo; Xiang Zeng; Lisi Zeng; Zhiyang Li; Xiaofang Deng; Xiaojun Tan; Weimin Hu
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

Review 2.  Structures of SF3b1 reveal a dynamic Achilles heel of spliceosome assembly: Implications for cancer-associated abnormalities and drug discovery.

Authors:  Debanjana Maji; Alan Grossfield; Clara L Kielkopf
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2019-11-09       Impact factor: 4.490

3.  Splice Modulation Synergizes Cell Cycle Inhibition.

Authors:  Kelsey A Trieger; James J La Clair; Michael D Burkart
Journal:  ACS Chem Biol       Date:  2020-02-17       Impact factor: 5.100

4.  Imaging of pre-mRNA splicing in living subjects using a genetically encoded luciferase reporter.

Authors:  Yaru Shi; Wei Liu; Haifeng Zheng; Zhiqiang Li; Xiaorui Shi; Shixuan Cai; Zhiqiang Jiao; Wenjie Mao; Jinrong Xie; Jie Tian; Fu Wang
Journal:  Biomed Opt Express       Date:  2018-01-08       Impact factor: 3.732

5.  Destabilization of the human RED-SMU1 splicing complex as a basis for host-directed antiinfluenza strategy.

Authors:  Usama Ashraf; Laura Tengo; Laurent Le Corre; Guillaume Fournier; Patricia Busca; Andrew A McCarthy; Marie-Anne Rameix-Welti; Christine Gravier-Pelletier; Rob W H Ruigrok; Yves Jacob; Pierre-Olivier Vidalain; Nicolas Pietrancosta; Thibaut Crépin; Nadia Naffakh
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-10       Impact factor: 11.205

6.  Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.

Authors:  Elisa Ten Hacken; Rebecca Valentin; Fara Faye D Regis; Jing Sun; Shanye Yin; Lillian Werner; Jing Deng; Michaela Gruber; Jessica Wong; Mei Zheng; Amy L Gill; Michael Seiler; Peter Smith; Michael Thomas; Silvia Buonamici; Emanuela M Ghia; Ekaterina Kim; Laura Z Rassenti; Jan A Burger; Thomas J Kipps; Matthew L Meyerson; Pavan Bachireddy; Lili Wang; Robin Reed; Donna Neuberg; Ruben D Carrasco; Angela N Brooks; Anthony Letai; Matthew S Davids; Catherine J Wu
Journal:  JCI Insight       Date:  2018-10-04

Review 7.  Splicing factor gene mutations in hematologic malignancies.

Authors:  Borja Saez; Matthew J Walter; Timothy A Graubert
Journal:  Blood       Date:  2016-12-09       Impact factor: 22.113

8.  Tumor-associated intronic editing of HNRPLL generates a novel splicing variant linked to cell proliferation.

Authors:  Yi-Tung Chen; Ian Yi-Feng Chang; Hsuan Liu; Chung-Pei Ma; Yu-Ping Kuo; Chieh-Tien Shih; Ying-Hsin Shih; Lin Kang; Bertrand Chin-Ming Tan
Journal:  J Biol Chem       Date:  2018-05-16       Impact factor: 5.157

Review 9.  Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.

Authors:  Laura M Urbanski; Nathan Leclair; Olga Anczuków
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-04-25       Impact factor: 9.957

10.  Prognostic alternative splicing signature in cervical squamous cell carcinoma.

Authors:  Hua-Yu Wu; Qi-Qi Li; Liang Liang; Lan-Lan Qiu; Hong-Wei Wei; Bing-Ying Huang; Chen Gang-; Rong-Quan He; Zhi-Guang Huang; Wei Hou; Qi-Ping Hu; Shang-Ling Pan
Journal:  IET Syst Biol       Date:  2020-12       Impact factor: 1.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.